乳腺癌原发灶与复发转移灶间ER、PR、HER-2、COX-2表达差异分析

Expressions of ER, PR, HER-2 and COX-2 in Primary and Metastatic Lesions of Breast Cancer

[目的]回顾性分析乳腺癌原发灶与转移灶中ER、PR、HER-2、COX-2表达的情况及临床意义。[方法]应用免疫组化的方法,检测了50例乳腺癌转移患者的ER、PR、HER-2、COX-2在原发灶与复发转移灶中的表达。[结果]乳腺癌原发灶与复发转移灶中ER阳性表达分别为70%和38%,有显著性差异(P=0.002)。PR、HER-2、COX-2在乳腺癌原发灶与复发转移灶中的表达差异无统计学意义(P>0.05)。原发灶与转移灶中HER-2与COX-2表达呈相关性(P<0.05)。[结论]乳腺癌原发灶和转移灶中ER、PR、HER-2、COX-2表达不一致,需根据转移灶受体的表达情况决定治疗方案。

[Purpose] To analyze the expressions of ER, PR, HER-2 and COX-2 in primary and metastatic lesions of breast cancer and their clinical significance. [Methods] The tissue samples from 50 breast cancer patients were collected. The expressions of ER, PR, HER-2 and COX-2 were detected by immunohistochemistry in both primary and metastatic lesions of breast cancer patients. [Results] Positive rates of ER in primary lesion and metastatic lesion were 70% and 38% respectively,with significantly different （P=0.002）. Positive rates of PR,HER-2, COX-2 in primary lesion were not significantly higher than those in metastatic lesion （P0.05）. COX-2 was related to HER-2 in primary and metastatic foci of breast cancer. [Conclusion] The expressions of ER, PR, HER-2 and COX-2 are inconsistent in primary and metastatic lesions of breast cancer, and treatment regimen should be made based on the receptor status of metastatic lesion.